



**Bruno Ledergerber**

**Kontakt**

Bruno Ledergerber

## Publikationen (67)

Schwenke J, Thorball C, Schoepf I, Ryom L, Hasse B, Lamy O, Calmy A, Wandeler G, Marzolini C, Kahlert C, Bernasconi E, Kouyos R, Günthard H, Ledergerber B, Fellay J, Burkhalter F, Tarr P, Swiss HIV Cohort Study S. Association of a Polygenic Risk Score With Osteoporosis in People Living With HIV: The Swiss HIV Cohort Study. *J Infect Dis* 2023; 228:742-750.

Schoepf I, Bernasconi E, Cavassini M, Buvelot H, Arribas J, Kouyos R, Fellay J, Günthard H, Tarr P, Seneghini M, Marzolini C, Thurnheer C, Thorball C, Ledergerber B, Kootstra N, Reiss P, Raffenberg M, Engel T, Braun D, Hasse B, Swiss HIV Cohort Study. Telomere Length Declines in Persons Living With HIV Before Antiretroviral Therapy Start But Not After Viral Suppression: A Longitudinal Study Over >17 Years. *J Infect Dis* 2021

Damas J, Hundsberger T, Di Benedetto C, Rossi S, Hasse B, Schlosser L, Du Pasquier R, Darling K, Cavassini M, Schmid P, Assal F, Ledergerber B, Nadin I, Tarr P, Stoeckle M, Kunze U, Hauser C, Gutbrod K, Calmy A, and the NAMACO study group. Neurocognitive course at 2-year follow-up in a Swiss cohort of people with well-treated HIV. *AIDS* 2021; 35:2469-2480.

Surial B, Rauch A, Wandeler G, Ledergerber B, Furrer H, Tarr P, Schmid P, Bernasconi E, Stöckle M, Günthard H, Cavassini M, Calmy A, Mugglin C, Swiss HIV Cohort Study. Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV : A Cohort Study. *Ann Intern Med* 2021; 174:758-767.

Schoepf I, Tarr P, Fellay J, Günthard H, Kouyos R, Buvelot H, Cavassini M, Bernasconi E, Seneghini M, Thurnheer C, Marzolini C, Hasse B, Reiss P, Kootstra N, Raffenberg M, Engel T, Ledergerber B, Thorball C, Swiss HIV Cohort Study. Coronary Artery Disease-Associated and Longevity-Associated Polygenic Risk Scores for Prediction of Coronary Artery Disease Events in Persons Living With Human Immunodeficiency Virus: The Swiss HIV Cohort Study. *Clin Infect Dis* 2021; 73:1597-1604.

Dietrich L, Tarr P, Ledergerber B, Fellay J, Buvelot H, Darling K, Bernasconi E, Schmid P, Maja W, Thurnheer M, Hasse B, Burkhalter F, Ryom L, Thorball C, Swiss HIV Cohort Study. Rapid Progression of Kidney Dysfunction in Swiss People Living with HIV: Contribution of Polygenic Risk Score and D:A:D Clinical Risk Score. *J Infect Dis* 2020

Braun D, Schmid P, Rougemont M, Delaloye J, Bernasconi E, Nicca D, Böni J, Rauch A, Kouyos R, Günthard H, Béguelin C, Stöckle M, Hampel B, Ledergerber B, Grube C, Nguyen H, Künzler-Heule P, Shah C, Salazar-Vizcaya L, Conen A, Flepp M, Fehr J. A treatment as prevention trial to eliminate hepatitis C among men who have sex with men living with HIV in the Swiss HIV Cohort Study. *Clin Infect Dis* 2020

Surial B, Wandeler G, Rauch A, Furrer H, Fux C, Schmid P, Bernasconi E, Stöckle M, Kovari H, Günthard H, Cavassini M, Calmy A, Ledergerber B, Swiss HIV Cohort Study. Changes in renal function after switching from TDF to TAF in HIV-infected individuals: a prospective cohort study. *J Infect Dis* 2020

Bayard C, Hasse B, Tarr P, Fux C, Di Benedetto C, Staehelin C, Weber R, Hoffmann M, Moulin E, Lecompte T, Flepp M, Ledergerber B, Swiss HIV Cohort Study. Associations Between Antiretroviral Treatment and Avascular Bone Necrosis: The Swiss HIV Cohort Study. *Open Forum Infect Dis* 2017; 4:ofx177.

Kovari H, Ledergerber B, Weber R, Bernasconi E, Stöckle M, Schmid P, Cavassini M, Rougemont M, Kouyos R, Rauch A, Swiss HIV Cohort Study. Hepatitis C Infection and the Risk of Non-Liver-Related Morbidity and Mortality in HIV-Infected Persons in the Swiss HIV Cohort Study. *Clin Infect Dis* 2017; 64:490-497.

Kovari H, Ledergerber B, Weber R, Bernasconi E, Stöckle M, Schmid P, Cavassini M, Rougemont M, Kouyos R, Rauch A. Hepatitis C infection and the risk of non-liver-related morbidity and mortality in HIV-positive persons in the Swiss HIV Cohort Study. *Clin Infect Dis* 2016

Sauter R, Held L, Günthard H, Rougemont M, Hoffmann M, Furrer H, Cavassini M, Bernasconi E, Battegay M, Ledergerber B, Huang R. CD4/CD8 ratio and CD8 counts predict CD4 response in HIV-1-infected drug naive and in patients on cART. *Medicine (Baltimore)* 2016; 95:e5094.

Junier T, Fellay J, Weber R, Brun Del Re C, Bernasconi E, Fux C, Schmid P, Kovari H, Bartha I, Barcelo C, Ledergerber B, Biver E, Rotger M, Tarr P. Contribution of Genetic Background and Clinical Risk Factors to Low-Trauma Fractures in Human Immunodeficiency Virus (HIV)-Positive Persons: The Swiss HIV Cohort Study. *Open Forum Infect Dis* 2016; 3:ofw101.

Anagnostopoulos A, Weber R, Jenewein J, Berney A, Calmy A, Barth J, Bernasconi E, Stoeckle M, Dietler S, Jaccard R, Ledergerber B, Swiss HIV Cohort Study. Frequency of and Risk Factors for Depression among Participants in the Swiss HIV Cohort Study (SHCS). *PloS one* 2015; 10:e0140943.

Kohler P, Vernazza P, Ledergerber B, Bernasconi E, Battegay M, Calmy A, Furrer H, Cavassini M, Schmidt A, and the Swiss HIV Cohort Study. The HIV care cascade in Switzerland: reaching the UNAIDS/WHO targets for patients diagnosed with HIV. *AIDS* 2015

Yang W, Swiss HIV Cohort Study (SHCS), Günthard H, Ledergerber B, Held L, Vernazza P, Bernasconi E, Cavassini M, Battegay M, Hirzel C, Aubert V, Klimkait T, Yerly S, Shah C, Böni J, Scherrer A, Kouyos R, Swiss HIV Cohort Study SHCS. Assessing efficacy of different nucleos(t)ide backbones in NNRTI-containing regimens in the Swiss HIV Cohort Study. *J Antimicrob Chemother* 2015

Bochud M, Simone E, Andrea F, Frei M, Claudius F, Jakob F, Ali G, Matthias G, Denis H, Marcel H, Walter H, Simon H, Felix H, Paul H, Eva K, Kaplan V, Peter D, Corinne C, Jean Michel G, Christoph H, Thomas L, Pedro M, Paccaud F, von Känel R, Aidacic V, Jürg B, Markus B, Heinz B, Martin B, Hans-Ulrich B, Ivo B, Reto C, Isabelle C, Daniel K, Stephan K, Beat K, Georg S, Pietro S, Jacques S, Alfred S, Alois S, Claudia S, Othmar S, Phuoc T, Marco V, Alessandro V, René V, Hans W, Fritz W, Johanna W, Joseph W, Frank S, Hana S, Benedict K, Heidi K, Vesna L, Giovanni L, Werner L, Phillippe L, Severin L, Christoph M, Jürgen M, Damian M, Werner M, Titus M, Valentina N, Jakob R, Rosemann T, Marco Z, Hasse B, CoLaus Cohort, FIRE and the Swiss HIV Cohort Study, Aubert V, Barth J, Battegay M, Bernasconi E, Böni J, Bucher H, Burton-Jeangros C, Calmy A, Cavassini M, Egger M, Elzi L, Fehr J, Fellay J, Furrer H, Ledergerber B, Vollenweider P, Tarr P, Marques-Vidal P, Waeber G, Preisig M, Mooser V, Valeri F, Djalali S, Rauch A, Bernasconi E, Calmy A, Cavassini M, Vernazza P, Battegay M, Weber R, Senn O, Fux C, Gorgievski M, Günthard H, Rauch A, Regenass S, Rickenbach M, Rudin C, Schöni-Affolter F, Schmid P, Schultze D, Schüpbach J, Speck R, Staehelin C, Tarr P, Telenti A, Trkola A, Weber R, Yerly S, Pantaleo G, Nadal D, Haerry D, Hasse B, Hirsch H, Hösli I, Kahlert C, Kaiser L, Keiser O, Klimkait T, Kouyos R, Kovari H, Ledergerber B, Martinetti G, Martinez de Tejada B, Metzner K, Müller N, Jean-Michel A. Strong Impact of Smoking on Multimorbidity and Cardiovascular Risk Among Human Immunodeficiency Virus-Infected Individuals in Comparison With the General Population. *Open Forum Infect Dis* 2015; 2:ofv108.

Carballo D, Calmy A, Ledergerber B, Keller P, Erne P, Fehr J, Cusini A, Schmid P, Fasel D, Bernasconi E, Clerc O, Hirschel B, Radovanovic D, Bähler C, Carballo S, Delhumeau C, Swiss HIV Cohort Study and AMIS registry. Increased mortality after a first myocardial infarction in human immunodeficiency virus-infected patients; a nested cohort study. *AIDS Res Ther* 2015; 12:4.

Gueler A, Egger M, Wandeler G, Ledergerber B, Cavassini M, Calmy A, Bucher H, Bertisch B, Moser A, Schoeni-Affolter F, Swiss HIV Cohort Study, Swiss National Cohort. Neighbourhood socio-economic position, late presentation and outcomes in people living with HIV in Switzerland. *AIDS* 2015; 29:231-8.

Yang W, Günthard H, Ledergerber B, Held L, Vernazza P, Bernasconi E, Cavassini M, Battegay M, Furrer H, Aubert V, Klimkait T, Yerly S, Shah C, Böni J, Scherrer A, Kouyos R, Swiss HIV Cohort Study. Assessing the Paradox Between Transmitted and Acquired HIV Type 1 Drug Resistance Mutations in the Swiss HIV Cohort Study From 1998 to 2012. *J Infect Dis* 2015

Kouyos R, Ledergerber B, Bernasconi E, Vernazza P, Battegay M, Cavassini M, Calmy A, Kovari H, Shah C, Aubert V, Klimkait T, Yerly S, Böni J, Yang W, Braun D, Rauch A, Günthard H. Higher Risk of Incident Hepatitis C Virus Coinfection Among Men Who Have Sex With Men, in Whom the HIV Genetic Bottleneck at Transmission Was Wide. *J Infect Dis* 2014; 210:1555–61.

Hasse B, Ledergerber B, Weber R, Di Benedetto C, Fellay J, Calmy A, Battegay M, Hoffmann M, Furrer H, Fehr J, Walker A, Swiss HIV Cohort Study. Co-trimoxazole prophylaxis is associated with reduced risk of incident tuberculosis in participants in the Swiss HIV Cohort Study. *Antimicrob Agents Chemother* 2014; 58:2363–8.

Kouyos R, Günthard H, Ledergerber B, Bernasconi E, Vernazza P, Battegay M, Cavassini M, Calmy A, Kovari H, Klimkait T, Aubert V, Shah C, Yerly S, Böni J, Rauch A, Swiss HIV Cohort Study (SHCS). Clustering of HCV coinfections on HIV phylogeny indicates domestic and sexual transmission of HCV. *Int J Epidemiol* 2014; 43:887–96.

Drescher S, Kouyos R, Günthard H, Ledergerber B, Vernazza P, Bernasconi E, Cavassini M, Ambrosioni J, Battegay M, Furrer H, Taffé P, Klimkait T, Aubert V, Shah C, Yerly S, Böni J, Yang W, von Wyl V, Swiss HIV Cohort Study. Treatment-naïve individuals are the major source of transmitted HIV-1 drug resistance in men who have sex with men in the Swiss HIV Cohort Study. *Clin Infect Dis* 2013; 58:285–94.

Scherrer A, Günthard H, Ledergerber B, Bernasconi E, Vernazza P, Elzi L, Cavassini M, Calmy A, Furrer H, Aubert V, Klimkait T, Yerly S, Böni J, the Swiss HIV Cohort Study (SHCS). Correction: Long-Lasting Protection of Activity of Nucleoside Reverse Transcriptase Inhibitors and Protease Inhibitors (PIs) by Boosted PI Containing Regimens. *PloS one* 2013; 8

Cusini A, Günthard H, Opravil M, Gutmann C, Zenger F, Klimkait T, Cavassini M, Gaudenz R, Hirschel B, Widmer N, Rohrbach J, Fux C, Ledergerber B, Decosterd L, Yerly S, Vernazza P, Swiss HIV Cohort Study. Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid. *J Acquir Immune Defic Syndr* 2013; 62:28–35.

Scherrer A, Günthard H, Ledergerber B, Bernasconi E, Vernazza P, Elzi L, Cavassini M, Calmy A, Furrer H, Aubert V, Klimkait T, Yerly S, Böni J, Swiss HIV Cohort Study (SHCS). Long-lasting protection of activity of nucleoside reverse transcriptase inhibitors and protease inhibitors (PIs) by boosted PI containing regimens. *PloS one* 2012; 7:e50307.

Elzi L, Battegay M, Weber R, Bernasconi E, Vernazza P, Hirschel B, Cavassini M, Ledergerber B, Furrer H, Erb S, for the Swiss HIV Cohort Study. Choice of Initial Combination Antiretroviral Therapy in Individuals With HIV Infection: Determinants and Outcomes. *Arch Intern Med* 2012:1–9.

Scherrer A, Günthard H, Bernasconi E, Vernazza P, Elzi L, Cavassini M, Calmy A, Furrer H, Cellera C, Klimkait T, Yerly S, Böni J, von Wyl V, Ledergerber B, Swiss HIV Cohort Study. Minor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patients. *PloS one* 2012; 7:e37983.

Pillai S, Wong J, Günthard H, Ledergerber B, Bernasconi E, Bregenzer A, Hirschel B, Battegay M, Fellay J, Rauch A, Kovari H, Greene W, Yukl S, Fujimoto K, Monto A, Skasko M, Guatelli J, Abdel-Mohsen M, Swiss HIV Cohort Study. Role of retroviral restriction factors in the interferon- $\alpha$ -mediated suppression of HIV-1 in vivo. *Proc Natl Acad Sci USA* 2012; 109:3035–40.

Keiser O, Egger M, Ledergerber B, Nicca D, Glass T, Cavassini M, Calmy A, Rauch A, Spycher B, Swiss HIV Cohort Study. Outcomes of antiretroviral therapy in the Swiss HIV Cohort Study: latent class analysis. *AIDS Behav* 2012; 16:245–55.

von Wyl V, Günthard H, Ledergerber B, Vernazza P, Hirschel B, Furrer H, Cavassini M, Bernasconi E, Battegay M, Klimkait T, Cellera C, Shah C, Böni J, Yerly S, Swiss HIV Cohort Study. Incidence of HIV-1 drug resistance among antiretroviral treatment-naïve individuals starting modern therapy combinations. *Clin Infect Dis* 2011; 54:131–40.

Scherrer A, Günthard H, Held L, Bernasconi E, Vernazza P, Elzi L, Cavassini M, Hirschel B, Rauch A, Bürgisser P, Klimkait T, Yerly S, Böni J, von Wyl V, Ledergerber B, Swiss HIV Cohort Study. Improved virological outcome in White patients infected with HIV-1 non-B subtypes compared to subtype B. *Clin Infect Dis* 2011; 53:1143-52.

Hasse B, Weber R, Bernasconi E, Bertisch B, Cavassini M, Hirschel B, Battegay M, Furrer H, Ledergerber B, Swiss HIV Cohort Study. Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. *Clin Infect Dis* 2011; 53:1130-9.

von Wyl V, Günthard H, Bonhoeffer S, Ledergerber B, Bernasconi E, Vernazza P, Battegay M, Staehelin C, Cavassini M, Hirschel B, Weber R, Klimkait T, Bürgisser P, Shah C, Böni J, Yerly S, Kouyos R, Swiss HIV Cohort Study. The role of migration and domestic transmission in the spread of HIV-1 non-B subtypes in Switzerland. *J Infect Dis* 2011; 204:1095-103.

Scherrer A, Günthard H, Ledergerber B, Bernasconi E, Vernazza P, Battegay M, Cavassini M, Hirschel B, Garzoni C, Bürgisser P, Klimkait T, Yerly S, Böni J, von Wyl V, Swiss HIV Cohort Study (SHCS). Viral suppression rates in salvage treatment with raltegravir improved with the administration of genotypic partially active or inactive nucleoside/tide reverse transcriptase inhibitors. *J Acquir Immune Defic Syndr* 2011; 57:24-31.

Haas A, Oxenius A, Günthard H, Macpherson A, Patuto N, Vernazza P, Hirschel B, Battegay M, Thurnheer M, Weber R, Bossart W, Ledergerber B, Rusert P, Slack E, Graw F, Zimmermann K, Swiss HIV Cohort Study. Systemic antibody responses to gut commensal bacteria during chronic HIV-1 infection. *Gut* 2011; 60:1506-19.

Ortiz M, Tarr P, Telenti A, Günthard H, Ledergerber B, Cavassini M, Hirschel B, Vernazza P, Bernasconi E, Elzi L, Arnedo M, Martinez R, Kovari H, Furrer H, Poloni E, Swiss HIV Cohort Study. No longitudinal mitochondrial DNA sequence changes in HIV-infected individuals with and without lipodystrophy. *J Infect Dis* 2011; 203:620-4.

Kouyos R, Cavassini M, Rauch A, Battegay M, Vernazza P, Bernasconi E, Ledergerber B, Bonhoeffer S, Günthard H, Hirschel B, Weber R, Klimkait T, von Wyl V, Yerly S, Böni J, Rieder P, Joos B, Taffé P, Shah C, Bürgisser P, Swiss HIV Cohort Study. Ambiguous nucleotide calls from population-based sequencing of HIV-1 are a marker for viral diversity and the age of infection. *Clin Infect Dis* 2011; 52:532-9.

Lubomirov R, Telenti A, Günthard H, Furrer H, Vernazza P, Elzi L, Bernasconi E, Hirschel B, Cavassini M, Martinez R, Ledergerber B, di Iulio J, Colombo S, the Swiss HIV Cohort Study. Association of Pharmacogenetic Markers with Premature Discontinuation of First-line Anti-HIV Therapy: An Observational Cohort Study. *J Infect Dis* 2010; 203:246-257.

Rotger M, Tarr P, Telenti A, Egger M, Ledergerber B, Weber R, Furrer H, Hirschel B, Bernasconi E, Cavassini M, Vernazza P, Elzi L, Taffé P, Martinez R, Gsponer T, Swiss HIV Cohort Study. Impact of single nucleotide polymorphisms and of clinical risk factors on new-onset diabetes mellitus in HIV-infected individuals. *Clin Infect Dis* 2010; 51:1090-8.

Hasse B, Weber R, Nicca D, Bernasconi E, Cavassini M, Elzi L, Evison J, Jeannin A, Glass T, Vernazza P, Hirschel B, Ledergerber B, Swiss HIV Cohort Study. Frequency and determinants of unprotected sex among HIV-infected persons: the Swiss HIV cohort study. *Clin Infect Dis* 2010; 51:1314-22.

Kouyos R, Bonhoeffer S, Ledergerber B, Rickenbach M, Bernasconi E, Vernazza P, Battegay M, Furrer H, Cavassini M, Hirschel B, Weber R, Klimkait T, Bürgisser P, Shah C, Taffé P, Böni J, Yerly S, von Wyl V, Günthard H. Molecular epidemiology reveals long-term changes in HIV type 1 subtype B transmission in Switzerland. *J Infect Dis* 2010; 201:1488-97.

Lubomirov R, Telenti A, Csajka C, Decosterd L, Buclin T, Descombes P, Rentsch K, Ledergerber B, Cavassini M, Calmy A, Vernazza P, Furrer H, Marzolini C, Martinez R, Colombo S, Fayet A, di Iulio J, Swiss HIV Cohort Study. ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir. *Pharmacogenet Genomics* 2010; 20:217-30.

Kovari H, Mueller N, Bernasconi E, Vernazza P, Foguena A, Hirschel B, Rauch A, Battegay M, Ledergerber B, Weber R. Incidence and risk factors for chronic elevation of alanine aminotransferase levels in HIV-infected persons without hepatitis b or c virus co-infection. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2010; 50:502-11.

Elzi L, Battegay M, Weber R, Bernasconi E, Vernazza P, Hirschel B, Cavassini M, Ledergerber B, Furrer H, Marzolini C, Swiss HIV Cohort Study. Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008. *Archives of internal medicine* 2010; 170:57-65.

Marzolini C, Battegay M, Back D, Ledergerber B, Khoo S, Vernazza P, Calmy A, Bernasconi E, Cavassini M, Chave J, Furrer H, Fux C, Weber R, Gibbons S, Elzi L, Swiss HIV Cohort Study. Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study. *Antivir Ther (Lond)* 2010; 15:413-23.

Rotger M, Tarr P, Telenti A, Ledergerber B, Weber R, Witteck A, Furrer H, Hirschel B, Battegay M, Bernasconi E, Cavassini M, Martinez R, Taffé P, Bayard C, Swiss HIV Cohort Study. Contribution of genome-wide significant single-nucleotide polymorphisms and antiretroviral therapy to dyslipidemia in HIV-infected individuals: a longitudinal study. *Circulation. Cardiovascular genetics* 2009; 2:621-8.

Kovari H, Weber R, Muellhaupt B, Mueller N, Calmy A, Schmid P, Jost J, Flepp M, Peter U, Ledergerber B, Swiss HIV Cohort Study. Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2009; 49:626-35.

von Wyl V, Günthard H, Ledergerber B, Bonhoeffer S, Francioli P, Vernazza P, Hirschel B, Furrer H, Cavassini M, Bernasconi E, Battegay M, Klimkait T, Bürgisser P, Yerly S, Swiss HIV Cohort Study. Long-term trends of HIV type 1 drug resistance prevalence among antiretroviral treatment-experienced patients in Switzerland. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2009; 48:979-87.

Ballif M, Weber R, Opravil M, Rickenbach M, Furrer H, Hirschel B, Schmid P, Bernasconi E, Cavassini M, Battegay M, Ledergerber B, Swiss HIV Cohort Study. Impact of previous virological treatment failures and adherence on the outcome of antiretroviral therapy in 2007. *PloS one* 2009; 4:e8275.

Vo T, Weber R, Vernazza P, Bernasconi E, Cavassini M, Battegay M, Furrer H, Hirschel B, Keiser O, Ledergerber B, Swiss HIV Cohort Study. Durability and outcome of initial antiretroviral treatments received during 2000--2005 by patients in the Swiss HIV Cohort Study. *The Journal of infectious diseases* 2008; 197:1685-94.

von Wyl V, Günthard H, Ledergerber B, Rickenbach M, Vernazza P, Hirschel B, Furrer H, Cavassini M, Bernasconi E, Battegay M, Klimkait T, Bürgisser P, Böni J, Yerly S, Swiss HIV Cohort Study. Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2008; 46:1299-309.

Berger S, Weber R, Battegay M, Ledergerber B, Vernazza P, Regli D, Furrer H, Zellweger C, Ehlert U, von Wyl V, Schad T, Gaab J. Effects of cognitive behavioral stress management on HIV-1 RNA, CD4 cell counts and psychosocial parameters of HIV-infected persons. *AIDS (London, England)* 2008; 22:767-75.

von Wyl V, Günthard H, Ledergerber B, Perrin L, Rickenbach M, Bernasconi E, Vernazza P, Hirschel B, Telenti A, Furrer H, Battegay M, Klimkait T, Bürgisser P, Böni J, Yerly S, for the Swiss HIV Cohort Study. Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types. *Archives of internal medicine* 2007; 167:1782-90.

Ledergerber B, Weber R, Egger M, Schmid P, Bernasconi E, Cavassini M, Hirschel B, Elzi L, Lehmann R, Rickenbach M, Furrer H, Swiss HIV Cohort Study. Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2007; 45:111-9.

Müller V, Bonhoeffer S, Günthard H, Vernazza P, Bernasconi E, Telenti A, Furrer H, Klimkait T, Perrin L, Ledergerber B, Swiss HIV Cohort Study. Stable virulence levels in the HIV epidemic of Switzerland over two decades. *AIDS (London, England)* 2006; 20:889-94.

Zinkernagel A, Weber R, Schmid P, Bernasconi E, Opravil M, Tarr P, Hirschel B, Battegay M, Furrer H, Rickenbach M, Ledergerber B, von Wyl V, Swiss HIV Cohort Study. Eligibility for and outcome of hepatitis C treatment of HIV-coinfected individuals in clinical practice: the Swiss HIV cohort study. *Antiviral therapy* 2006; 11:131-42.

Karrer U, Speck R, Weber R, Russotti M, Schmid P, Hirschel B, Gayet-Ageron A, Cavassini M, Battegay M, Elzi L, Furrer H, Ledergerber B, Swiss HIV Cohort Study. Dose-dependent influence of didanosine on immune recovery in HIV-infected patients treated with tenofovir. *AIDS (London, England)* 2005; 19:1987-94.

Kaufmann G, Battegay M, Hirschel B, Rickenbach M, Bernasconi E, Cavassini M, Vernazza P, Opravil M, Perrin L, Ledergerber B, Furrer H, Swiss HIV Cohort Study. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2005; 41:361-72.

Tarr P, Telenti A, Ledergerber B, Rickenbach M, Darioli R, Bernasconi E, Vernazza P, Weber R, Battegay M, Hirschel B, Martinez R, Rotger M, Furrer H, Bleiber G, Taffé P, Swiss HIV Cohort Study. Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders. *The Journal of infectious diseases* 2005; 191:1419-26.

Opravil M, Perrin L, Ledergerber B, Vernazza P, Blasko M, Bernasconi E, Calmy A, Furrer H, Chave J, Baumann D, Swiss HIV Cohort Study. Long-term efficacy after switch from protease inhibitor-containing highly active antiretroviral therapy to abacavir, lamivudine, and zidovudine. *AIDS (London, England)* 2004; 18:2213-5.

Kaufmann G, Battegay M, Hirschel B, Rickenbach M, Bernasconi E, Vernazza P, Ledergerber B, Cavassini M, Furrer H, Perrin L, Weber R, Khanna N, Swiss HIV Cohort Study. Long-term virological response to multiple sequential regimens of highly active antiretroviral therapy for HIV infection. *Antiviral therapy* 2004; 9:263-74.

Kaufmann G, Battegay M, Egger M, Rickenbach M, Bernasconi E, Vernazza P, Ledergerber B, Hirschel B, Telenti A, Furrer H, Opravil M, Pantaleo G, Perrin L, Swiss HIV Cohort Study Group. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. *Archives of internal medicine* 2003; 163:2187-95.

Jaggy C, Hirschel B, Bernasconi E, Vernazza P, Flepp M, Battegay M, Telenti A, Furrer H, Rickenbach M, Egger M, Schwarz C, Ledergerber B, von Overbeck J, Swiss HIV Cohort Study. Mortality in the Swiss HIV Cohort Study (SHCS) and the Swiss general population. *Lancet* 2003; 362:877-8.

Greub G, Telenti A, Phillips A, Hirschel B, Günthard H, Bernasconi E, Vernazza P, Battegay M, Furrer H, Francioli P, Miller V, Perrin L, Staszewski S, Ledergerber B, Cozzi-Lepri A, Frankfurt HIV Clinic Cohort and the Swiss HIV Cohort Study. Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy. *AIDS* (London, England) 2002; 16:1967-9.

Opravil M, Perrin L, Weber R, Howe C, Günthard H, Ledergerber B, Battegay M, Bernasconi E, Vernazza P, Fischer M, Bisset L, Yerly S, Chave J, Furrer H, Lazzarin A, Hirschel B, Swiss HIV Cohort Study. A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection. *The Journal of infectious diseases* 2002; 185:1251-60.



## Projekte (0)

Keine Resultate gefunden.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)